JP2017523984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523984A5 JP2017523984A5 JP2017506286A JP2017506286A JP2017523984A5 JP 2017523984 A5 JP2017523984 A5 JP 2017523984A5 JP 2017506286 A JP2017506286 A JP 2017506286A JP 2017506286 A JP2017506286 A JP 2017506286A JP 2017523984 A5 JP2017523984 A5 JP 2017523984A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- pharmaceutical composition
- ox40l
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032959P | 2014-08-04 | 2014-08-04 | |
| US62/032,959 | 2014-08-04 | ||
| PCT/US2015/043408 WO2016022468A1 (en) | 2014-08-04 | 2015-08-03 | Antagonistic anti-ox40l antibodies and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523984A JP2017523984A (ja) | 2017-08-24 |
| JP2017523984A5 true JP2017523984A5 (cg-RX-API-DMAC7.html) | 2018-08-30 |
| JP6628787B2 JP6628787B2 (ja) | 2020-01-15 |
Family
ID=55264394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506286A Active JP6628787B2 (ja) | 2014-08-04 | 2015-08-03 | 拮抗性抗ｏｘ４０ｌ抗体およびそれらの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10167339B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3194445A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6628787B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107074951B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015301338C1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL250428B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016022468A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US20220372153A1 (en) * | 2015-03-03 | 2022-11-24 | Kymab Limited | Synergistic combinations of ox40l antibodies for the treatment of gvhd |
| US9434785B1 (en) | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018170764A1 (zh) * | 2017-03-22 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | 一种用于 RNAi 的载体及其应用 |
| SG11202003078VA (en) * | 2017-10-18 | 2020-05-28 | Alpine Immune Sciences Inc | Variant icos ligand immunomodulatory proteins and related compositions and methods |
| CN108458964A (zh) * | 2017-10-31 | 2018-08-28 | 天津协和华美医学诊断技术有限公司 | 一种抗体组合物及其在淋巴浆细胞性淋巴瘤微小残留检测中的应用 |
| CA3129302A1 (en) * | 2019-03-12 | 2020-09-17 | Richard BROKX | Tsg-6 antibodies and uses therefor |
| WO2021110817A1 (en) * | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l |
| AU2021259628A1 (en) * | 2020-04-24 | 2023-01-05 | Millennium Pharmaceuticals, Inc. | Anti-CD19 antibodies and uses thereof |
| KR102705172B1 (ko) * | 2020-12-09 | 2024-09-11 | 에이치케이이노엔 주식회사 | 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도 |
| AU2020480890A1 (en) * | 2020-12-09 | 2023-07-27 | Hk Inno.N Corporation | ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFα BISPECIFIC ANTIBODY, AND USES THEREOF |
| JP2024530954A (ja) * | 2021-08-10 | 2024-08-27 | カイマブ・リミテッド | アトピー性皮膚炎の処置 |
| TW202521577A (zh) * | 2023-08-04 | 2025-06-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｏｘ４０ｌ抗體以及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3914342B2 (ja) * | 1997-09-25 | 2007-05-16 | 武田薬品工業株式会社 | ｇｐ３４結合阻害物を有効成分として含有する医薬組成物 |
| US7291331B1 (en) * | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| TWI380996B (zh) * | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| AR057253A1 (es) * | 2005-12-16 | 2007-11-21 | Genentech Inc | Anticuerpos anti-ox40l y metodos que los utilizan |
| US8962807B2 (en) * | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
| US20120020960A1 (en) | 2010-07-26 | 2012-01-26 | Baylor Research Institute | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
-
2015
- 2015-08-03 CN CN201580052180.0A patent/CN107074951B/zh active Active
- 2015-08-03 AU AU2015301338A patent/AU2015301338C1/en active Active
- 2015-08-03 JP JP2017506286A patent/JP6628787B2/ja active Active
- 2015-08-03 WO PCT/US2015/043408 patent/WO2016022468A1/en not_active Ceased
- 2015-08-03 EP EP15829426.4A patent/EP3194445A4/en active Pending
- 2015-08-03 US US15/501,526 patent/US10167339B2/en active Active
-
2017
- 2017-02-02 IL IL250428A patent/IL250428B/en active IP Right Grant
-
2018
- 2018-12-05 US US16/210,188 patent/US10570208B2/en active Active